CM Management’s Cytokinetics CYTK Stock Holding History

CM Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40,000	Closed	-$1.61M	–	70
2025 Q1	$1.61M	Buy	+40,000	New	+$1.84M	1.62%	29
2023 Q3	–	Sell	-10,000	Closed	-$326K	–	71
2023 Q2	$326K	Sell	10,000 -25,000	-71%	-$925K	0.32%	61
2023 Q1	$1.23M	Sell	35,000 -15,000	-30%	-$612K	1.46%	24
2022 Q4	$2.29M	Hold	50,000	–	–	2.74%	13
2022 Q3	$2.42M	Sell	50,000 -50,000	-50%	-$2.41M	2.7%	10
2022 Q2	$3.93M	Sell	100,000 -120,000	-55%	-$4.83M	4.18%	4
2022 Q1	$8.1M	Sell	220,000 -55,000	-20%	-$1.95M	6.8%	1
2021 Q4	$12.5M	Hold	275,000	–	–	9.47%	1
2021 Q3	$9.83M	Sell	275,000 -50,000	-15%	-$1.47M	7.33%	1
2021 Q2	$6.43M	Hold	325,000	–	–	4.65%	2
2021 Q1	$7.56M	Hold	325,000	–	–	5.62%	1
2020 Q4	$6.75M	Buy	+325,000	New	+$5.94M	6.26%	1

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

CM Management's CYTK Position: Q2 2025 in Review

CM Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 40,000 shares — an estimated $1.61M sold.

CM Management first reported a position in CYTK in Q4 2020 and held it in 12 quarters. The position peaked at $12.5M in Q4 2021. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

CM Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
CM Management sold 40,000 Cytokinetics shares in Q2 2025, an estimated $1.61M.
CM Management first reported a position in Cytokinetics in Q4 2020 and held it in 12 quarters.
CM Management's Cytokinetics position peaked at $12.5M in Q4 2021.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on CM Management's 13F filing for Q2 2025, filed 12 Aug 2025.